Literature DB >> 21229293

Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients.

Paola Gaviani, A Salmaggi, A Silvani.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21229293     DOI： 10.1007/s11060-010-0515-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  5 in total

1.  Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

Authors:  M Gander; S Leyvraz; L Decosterd; M Bonfanti; C Marzolini; F Shen; D Liénard; L Perey; G Colella; J Biollaz; F Lejeune; D Yarosh; M Belanich; M D'Incalci
Journal:  Ann Oncol       Date:  1999-07       Impact factor: 32.976

2.  Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Authors:  Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andrea Salmaggi; Chiara Falcone; Graziella Filippini; Andrea Botturi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2007-06-19       Impact factor: 4.130

3.  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  J Plowman; W R Waud; A D Koutsoukos; L V Rubinstein; T D Moore; M R Grever
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

4.  Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.

Authors:  Susan M Chang; Michael D Prados; W K Alfred Yung; Howard Fine; Larry Junck; Harry Greenberg; H Ian Robins; Minesh Mehta; Karen L Fink; Kurt A Jaeckle; John Kuhn; Kenneth Hess; Clifford Schold
Journal:  Cancer       Date:  2004-04-15       Impact factor: 6.860

5.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Authors:  Antje Wick; Jörg Felsberg; Joachim P Steinbach; Ulrich Herrlinger; Michael Platten; Britta Blaschke; Richard Meyermann; Guido Reifenberger; Michael Weller; Wolfgang Wick
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544
  5 in total
  7 in total

Review 1.  Nonsurgical treatment of recurrent glioblastoma.

Authors:  O Gallego
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

Review 2.  Standards of care for treatment of recurrent glioblastoma--are we there yet?

Authors:  Michael Weller; Timothy Cloughesy; James R Perry; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2012-11-07       Impact factor: 12.300

3.  The future of high-grade glioma: Where we are and where are we going.

Authors:  Emilie Le Rhun; Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2015-02-13

Review 4.  Recurrent Glioblastoma: Where we stand.

Authors:  Sanjoy Roy; Debarshi Lahiri; Tapas Maji; Jaydip Biswas
Journal:  South Asian J Cancer       Date:  2015 Oct-Dec

5.  Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.

Authors:  Yu Wang; Xiangyi Kong; Yi Guo; Renzhi Wang; Wenbin Ma
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 6.  An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.

Authors:  Giuseppe Lombardi; Patrizia Farina; Alessandro Della Puppa; Diego Cecchin; Ardi Pambuku; Luisa Bellu; Vittorina Zagonel
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

7.  The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Authors:  Michele Guida; Stefania Tommasi; Sabino Strippoli; Maria Iole Natalicchio; Simona De Summa; Rosamaria Pinto; Antonio Cramarossa; Anna Albano; Salvatore Pisconti; Michele Aieta; Ruggiero Ridolfi; Amalia Azzariti; Gabriella Guida; Vito Lorusso; Giusepe Colucci
Journal:  BMC Cancer       Date:  2018-05-10       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.